HAE patients get new option as NICE backs Takeda's Takhzyro

Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in

Who will be the biggest pharma players in orphan drugs?

New analysis from GlobalData has identified the predicted top 15 pharma players in 2025 for organ drugs, with Roche coming out in the lead.

The top pharma companies by revenue 2018

Sosei Heptares bags another big partnership, this time with ...

Takeda looking to divest portfolio of older drugs in Europe

Takeda is trying to sell a portfolio of older drugs in western Europe as it seeks to cut its debts following the $59 billion purchase of Shire.

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...